Longterm corticosteroid use after liver transplantation for autoimmune hepatitis is safe and associated with a lower incidence of recurrent disease

Thinesh L. Krishnamoorthy, Joanna Miezynska‐Kurtycz, James Hodson, Bridget K. Gunson, James Neuberger, Piotr Milkiewicz, Ye H. Oo – 3 September 2015 – Patients transplanted for autoimmune hepatitis (AIH) are at risk of recurrent disease. Our current practice is to maintain long‐term low‐dose corticosteroids with additional immunosuppressive agents. This study describes the implications on patients' outcomes, sepsis, and osteoporosis. We collected data on patients transplanted between January 1999 and October 2014 in a single center who survived for more than 6 months.

Keeping high model for end‐stage liver disease score liver transplantation candidates alive

Jacqueline G. O'Leary, Susan L. Orloff, Josh Levitsky, Paul Martin, David P. Foley – 3 September 2015 – As the mean Model for End‐Stage Liver Disease (MELD) score at time of liver transplantation continues to increase, it is crucial to implement preemptive strategies to reduce wait‐list mortality. We review the most common complications that arise in patients with a high MELD score in an effort to highlight strategies that can maximize survival and successful transplantation. Liver Transpl 21:1428‐1437, 2015. © 2015 AASLD.

Emergence of linezolid resistance in hepatobiliary infections caused by Enterococcus faecium

Marc Niebel, M. Thamara P. R. Perera, Tahir Shah, Ravi Marudanayagam, Kate Martin, Beryl A. Oppenheim, Miruna D. David – 3 September 2015 – Enterococcal infections are common in liver transplantation and hepatopancreaticobiliary (HPB) surgery. Linezolid is frequently used to treat not only vancomycin‐resistant Enterococcus (VRE), but also vancomycin‐sensitive Enterococcus (VSE) infections, and resistance can develop.

Exendin‐4 attenuates brain death–induced liver damage in the rat

Rodrigo Carlessi, Natalia E. Lemos, Ana L. Dias, Leticia A. Brondani, Jarbas R. Oliveira, Andrea C. Bauer, Cristiane B. Leitão, Daisy Crispim – 3 September 2015 – The majority of liver grafts destined for transplantation originate from brain dead donors. However, significantly better posttransplantation outcomes are achieved when organs from living donors are used, suggesting that brain death (BD) causes irreversible damage to the liver tissue. Recently, glucagon‐like peptide‐1 (GLP1) analogues were shown to possess interesting hepatic protection effects in different liver disease models.

Subscribe to